VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study

NAMUR, Belgium, April 8, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced that first results from a prostate cancer study by the Company will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the most prestigious meetings on preclinical research in the field of oncology. The meeting is being held April 16-20, 2016 in New Orleans, LA.

VolitionRx Chief Scientific Officer, Jake Micallef, PhD, MBA will present a poster that will include results from a study to assess the feasibility of using the Company's NuQ^® blood tests to detect prostate cancer. The trial was conducted in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK. In addition, Dr Micallef will discuss data announced recently from clinical trials by VolitionRx, including colorectal cancer and high-risk colorectal adenomas, pancreatic cancer and non-small cell lung cancer (NSCLC) cases.

Logistical details of the presentation are as follows:

Abstract #4476 / Poster #20: Epigenetically altered circulating nucleosomes as blood biomarkers for early detection of cancer: clinical studies in NSCLC, CRC, PCA and PC

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The NuQ^® tests are based on the science of Nucleosomics^® which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

An animation introducing VolitionRx's Nucleosomics^® technology can be found at: https://www.youtube.com/watch?v=38dodCpyXf0.

Media Contacts
Anita Heward, VolitionRx
a.heward@volitionrx.com 
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (508) 280-6592

Investor Contacts
Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements.  These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics^®, NuQ^® and HyperGenomics^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-to-present-at-aacr-annual-meeting-and-announce-first-results-from-prostate-cancer-study-300248388.html

SOURCE VolitionRx Ltd